Fludarabine, Bendamustine, and Rituximab (FBR) for Relapsed Chronic Lymphocytic Leukemia (CLL)
Status:
Completed
Trial end date:
2017-03-31
Target enrollment:
Participant gender:
Summary
The goal of Phase 1 of this clinical research study is to find the highest tolerable dose of
bendamustine, combined with fludarabine and rituximab, that can be given to patients who have
CLL that has been treated before.
The goal of Phase 2 of this study is to find out if this drug combination can help to control
the disease. The safety of this drug combination will also be studied.